Natural Disease Progress of Dupuytren Disease (DD)

December 4, 2023 updated by: D.C. Broekstra, University Medical Center Groningen

Dupuytren disease (DD) is a progressive fibromatosis of the palmar fascias of the hand and fingers, which may lead to extension deficits of the fingers. The disease can be very disabling in moderate and severe cases, whereby performing normal daily activities can become very problematic. The aetiology and pathogenesis are not completely understood. There is a genetic disposition and it is influenced by environmental factors. The disease is especially prevalent in white males of Northern European descent above 50 years of age. There is paucity of knowledge about the natural progression of the disease. Several studies have been conducted on progression of disease and from these studies it becomes obvious that the disease is progressive over several years. However, in most studies only one moment of follow-up has taken place, so the course of the progression over time is unknown.

The aim of this study is to enhance our knowledge on the natural disease progression of DD at different stages.

Study Overview

Status

Completed

Detailed Description

Objective:

  • Primary objective: To study natural disease progress of Dupuytren Disease (DD) in different stages of disease in males and females above 18 years of age.
  • Secondary objectives:

    1. To study the effect of potential risk factors for DD on natural disease progress.
    2. To study at what stage of disease patients with DD experience problems in daily life.
    3. To study the incidence and course of recurrent disease. Primary Hypothesis: The natural course of disease is an exponential function of time.
    4. To study the intrarater reliability of the measurements

    f. To determine whether the echogenicity of the nodules can predict progression g. To determine whether extension deficit measurements can be replaced by measurements of extension, and whether this will facilitate the statistical analysis h. To determine the association between passive and active measurements of extension and extension deficit, and to see whether active measurements can be derived from passive measurements and vice versa.

  • Study design: The study is designed as a prospective observational pilot study with a follow-up of 10 years.
  • Study population: Males and females above 18 years of age with all stages of primary Dupuytren's disease in at least one hand
  • Main study parameters/endpoints: The natural course of progression of DD measured as the increase or decrease in size of nodules and cords in millimetres and/or increase of total passive extension deficit in degrees, from baseline to endpoint.
  • Secondary study parameters:

    1. Patient-reported hand function (Michigan Hand Outcomes Questionnaire (MHOQ), Patient-Rated Wrist/Hand Evaluation (PRWHE) and Unité Rhumatologique des Affections de la Main (URAM) scale
    2. incidence and course of recurrent disease
    3. disease activity (ultrasonography and tonometry)
  • Procedure Patients visit the outpatient clinic every 6 months (first 5 years of follow-up) and later on every 12 months (last 5 years of follow-up) for an anamnestic interview, physical examination of the hands, ultrasonography, tonometry and for filling out the PROMs.

Study Type

Observational

Enrollment (Actual)

261

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Groningen, Netherlands, 9700 RB
        • University Medical Center Groningen

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Patients with Dupuytren Disease who participated in prior studies and patients from the outpatient clinic

Description

Inclusion Criteria:

  • Patients (> 18 years of age) with primary Dupuytren's disease in all Tubiana stages
  • Operated hands of patients with primary Dupuytren's disease on the contra lateral hand

Exclusion Criteria:

  • Patients who are incapable of giving consent
  • Patients who are not able or not willing to visit the UMCG for follow-up
  • Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The course of DD: passive and active extension deficit and dimension of palpable nodules and cords
Time Frame: every 6-12 months
Active and passive extension deficit is measured with a goniometer at joint level Dimension of nodules and cords is measured using a tumorimeter
every 6-12 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Disease activity: Echogenicity and nodule hardness
Time Frame: every 12 months, starting from 2016 (ultrasound) and 2018 (tonometry)
Activity of a nodule is determined by 1) echogenicity of the ultrasound image in sagittal and transversal plane, 2) hardness of the nodule determined by tonometry
every 12 months, starting from 2016 (ultrasound) and 2018 (tonometry)
Patient-reported hand function: MHQ, PRWHE and URAM
Time Frame: every 6-12 months
To study what problems patients with DD experience in daily life, PROMs are used. MHQ and PRWHE in the first 2 years, URAM later on
every 6-12 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Paul MN Werker, PhD, University Medical Center Groningen

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 22, 2012

Primary Completion (Actual)

March 1, 2023

Study Completion (Actual)

March 20, 2023

Study Registration Dates

First Submitted

August 9, 2013

First Submitted That Met QC Criteria

August 13, 2013

First Posted (Estimated)

August 14, 2013

Study Record Updates

Last Update Posted (Estimated)

December 5, 2023

Last Update Submitted That Met QC Criteria

December 4, 2023

Last Verified

December 1, 2023

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

There is no plan available, but we are open for collaboration

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Disease Progression

3
Subscribe